NR1H4 and hepatocellular carcinoma: The results of serum TBA content detection in patients with hepatocellular carcinoma and obstructive jaundice treated with FXR inhibitor showed that the serum TBA content was 13.5 ± 0.4 mmol/L and the intrahepatic TBA content was 34.6 ± 0.6 mmol/L in the control group.